Viruses · 2023 · 16 citations · 28 references
Life SciencesImmunologyInfectious DiseasesHost-pathogen InteractionsImmunogeneticsInnate ImmunityInfectious Disease SusceptibilityInnate Immune Gene PolymorphismsInnate Immune ReceptorsInnate Immune RecognitionInnate Immune ResponseSusceptibility To InfectionClinical ProgressionDisease PrognosisInfection Risk FactorsInnate Immune Receptor VariationInnate Immune SusceptibilityInnate Immunity Gene VariantsSars-cov-2 InfectionSars-cov-2 Pneumonia
COVID-19 is characterized by a heterogeneous clinical presentation and prognosis. Risk factors contributing to the development of severe disease include old age and the presence of comorbidities. However, the genetic background of the host has also been recognized as an important determinant of disease prognosis. Considering the pivotal role of innate immunity in the control of SARS-CoV-2 infection, we analyzed the possible contribution of several innate immune gene polymorphisms (including TLR2-rs5743708, TLR4-rs4986790, TLR4-rs4986791, CD14-rs2569190, CARD8-rs1834481, IL18-rs2043211, and CD40-rs1883832) in disease severity and prognosis. A total of 249 individuals were enrolled and further divided into five (5) groups, according to the clinical progression scale provided by the World Health Organization (WHO) (asymptomatic, mild, moderate, severe, and critical). We identified that elderly patients with obesity and/or diabetes mellitus were more susceptible to developing pneumonia and respiratory distress syndrome after SARS-CoV-2 infection, while the IL18-rs1834481 polymorphism was an independent risk factor for developing pneumonia. Moreover, individuals carrying either the TLR2-rs5743708 or the TLR4-rs4986791 polymorphisms exhibited a 3.6- and 2.5-fold increased probability for developing pneumonia and a more severe disease, respectively. Our data support the notion that the host’s genetic background can significantly affect COVID-19 clinical phenotype, also suggesting that the IL18-rs1834481, TLR2-rs5743708, and TLR4-rs4986791 polymorphisms may be used as molecular predictors of COVID-19 clinical phenotype.
28
Tamara Silva Rodrigues, Keyla Santos Guedes de Sá, Adriene Y. Ishimoto et al. · The Journal of Experimental Medicine · 2020 · 855 citations · Full text
TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines
Min Zheng, Rajendra Karki, Evan P. Williams et al. · Nature Immunology · 2021 · 617 citations · Full text
Abhigyan Choudhury, Suprabhat Mukherjee · Journal of Medical Virology · 2020 · 509 citations · Full text
Lyudmyla Kompaniyets, Audrey F. Pennington, Alyson B. Goodman et al. · Preventing Chronic Disease · 2021 · 364 citations · Full text
Public Health, Chronic Disease Prevention, Health Promotion +13